Abstract
Docetaxel (DTX) is an important broad-spectrum antitumor drug, but poor water solubility and multidrug resistance often limit clinical application. A nitric oxide (NO) donor docetaxel prodrug (DISMN-DTX) was designed and synthesized, through a two-step procedure starting from isosorbide mononitrate. The novel amphiphilic small molecule prodrug is readily self-assembled into nanoplatforms, which effectively solves the significant obstacle of poor water solubility of DTX. Specifically, the DISMN-DTX nanoplatforms could trigger NO release at the intracellular reduction conditions to improve the chemosensitivity of DTX. Thus, our rationally designed prodrug nanoplatforms provide an efficient treatment option for drug-resistant tumors.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
